Eines der Hauptziele von Life4me+ — ist neue Fälle von HIV und anderen STIs, Hepatitis C und Tuberkulose zu verhindern.

Die App hilft, eine Kommunikation zwischen Ärzten und HIV-positiven Menschen aufzubauen. Die App erlaubt Ihnen, einen Zeitplan für Ihre Medikamenteneinnahme bequem zu organisieren – dies geschieht über eine für Dritte nicht nachvollziehbare und personalisierte Erinnerung.

Alle Nachrichten / Dezember 2016

Archiv

✕

27 Dezember 2016

11945

Cameroon: 50 people were convicted of homosexuality between 2010 and 2014

Cameroon: 50 people were convicted of homosexuality between 2010 and 2014

Cameroon is still prosecutes people for being gay more aggressively than almost any other nation in the world. According to data collected by The Cameroonian Foundation for AIDS, at least 50 people in Cameroon were convicted of homosexuality between 2010 and 2014 for acts ...

26 Dezember 2016

12152

Sweden, Denmark and Norway to increase their contribution to UNAIDS next year

Sweden, Denmark and Norway to increase their contribution to UNAIDS next year

UNAIDS has published a press release in which welcomes new funding commitments from 3 Nordic countries for 2017.

25 Dezember 2016

11494

UK: 40% drop in new HIV infections

UK: 40% drop in new HIV infections

The largest sexual health clinic in the UK has reported a dramatic drop in the number of people they have diagnosed with HIV this year.

22 Dezember 2016

11228

Janssen Sciences: Investigational two-drug HIV regimen showed positive results

Janssen Sciences: Investigational two-drug HIV regimen showed positive results

Janssen Sciences Ireland UC (Janssen) announced the results from first phase III studies of investigational two-drug HIV treatment regimen. Two Phase III studies were designed to evaluate the safety and efficacy of switching virologically suppressed patients from a three ...

21 Dezember 2016

12534

Study: Drugs for HIV and Hepatitis C treatment can cause side effects when used together

Study: Drugs for HIV and Hepatitis C treatment can cause side effects when used together

Study: Use of direct-acting antivirals for the treatment of Hepatitis C virus infection, which contain sofosbuvir can lead to Hepatitis B reactivation in the body, as well as to interact with HIV drug tenofovir disoproxil.

21 Dezember 2016

13964

GSK to test injectable drug for PrEP

GSK to test injectable drug for PrEP

GlaxoSmithKline had started a large study to test an experimental long-acting injection for preventing of HIV infection. The drug cabotegravir, an injectable medication, which if effective might become an alternative to Truvada.

21 Dezember 2016

12934

Study: Drugs for HIV and Hepatitis C treatment can cause side effects when used together

Study: Drugs for HIV and Hepatitis C treatment can cause side effects when used together

According to a study published by University of Rhode Island pharmacy professor and a graduate student in the Journal of Hepatology, use of direct-acting antivirals for the treatment of Hepatitis C virus infection , such as Sovaldi, Harvoni and Epclusa, which contain sofosbuvir ...

20 Dezember 2016

13482

Dolutegravir quickly reduces viral load in semen

Dolutegravir quickly reduces viral load in semen

According to the new study published in the Journal of Infectious Diseases, dolutegravir (Tivicay) is able to dramatically reduce the viral load in semen. Semen is thought to be a reservoir of the virus and other antiviral drugs have difficult time reaching this area. It ...

20 Dezember 2016

10713

Study: sex-race health disparities in the occurrence of chronic diseases associated with ageing

Study: sex-race health disparities in the occurrence of chronic diseases associated with ageing

A group of researchers from the United States have published the results of a study regarding ART-treated people and sex-race disparities in the occurrence of chronic diseases associated with ageing. The study was published in the online edition of Clinical Infectious Diseases. ...

19 Dezember 2016

11698

Ibalizumab might be the answer for patients with drug resistance

Ibalizumab might be the answer for patients with drug resistance

According to the results from a Phase 3 trial published in October, an experimental injectable drug, ibalizumab, might be an option for patients struggling with drug resistance. Drug resistant strains are now a major threat to effective HIV treatment worldwide. Patients ...

1 2 3...5